Dyne Therapeutics (Dyne Therapeutics) EV-to-EBIT

: -8.42 (As of Today)

View and export this data going back to 2020. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Dyne Therapeutics's Enterprise Value is $2,038.94 Mil. Dyne Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-242.16 Mil. Therefore, Dyne Therapeutics's EV-to-EBIT for today is -8.42.

The historical rank and industry rank for Dyne Therapeutics's EV-to-EBIT or its related term are showing as below:

DYN' s EV-to-EBIT Range Over the Past 10 Years
Min: -99999999.99 Med: 0 Max: 99999999.99
Current: -8.42

During the past 6 years, the highest EV-to-EBIT of Dyne Therapeutics was 99999999.99. The lowest was -99999999.99. And the median was 0.00.

DYN's EV-to-EBIT is ranked worse than
100% of 441 companies
in the Biotechnology industry
Industry Median: 8.62 vs DYN: -8.42

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Dyne Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $721.85 Mil. Dyne Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-242.16 Mil. Dyne Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -33.55%.

Dyne Therapeutics EV-to-EBIT Historical Data

The historical data trend for Dyne Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dyne Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

-10.18

-1.79

-2.45

-2.98

Dyne Therapeutics Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT																-2.45	-2.56	-2.61	-1.96	-2.98

Competitive Comparison

For the Biotechnology subindustry, Dyne Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dyne Therapeutics EV-to-EBIT Distribution

For the Biotechnology industry and Healthcare sector, Dyne Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Dyne Therapeutics's EV-to-EBIT falls into.

Dyne Therapeutics EV-to-EBIT Calculation

Dyne Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	2038.937	/	-242.161
	=	-8.42

Dyne Therapeutics's current Enterprise Value is $2,038.94 Mil.
Dyne Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-242.16 Mil.

Dyne Therapeutics (NAS:DYN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Dyne Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-242.161	/	721.84871
	=	-33.55 %

Dyne Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $721.85 Mil.
Dyne Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-242.16 Mil.

Dyne Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Dyne Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Dyne Therapeutics (Dyne Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dyne Therapeutics Inc (NAS:DYN) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

1560 Trapelo Road, Waltham, MA, USA, 02451

Website

https://www.dyne-tx.com

Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy.

Executives

Dirk Kersten	director, 10 percent owner	C/O FORBION CAPITAL FUND IV COOPERATIEF, GOOMIER 2-35, NAARDEN P7 14111 DC
Joshua T Brumm	director, officer: See Remarks	ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Jonathan Mcneill	officer: See Remarks	C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Oxana Beskrovnaya	officer: See Remarks	C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Richard William Scalzo	officer: See Remarks	25 ALBERTA LANE, HOLLISTON MA 01746
Wildon Farwell	officer: Chief Medical Officer	C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET MA 02451
Susanna Gatti High	officer: Chief Operating Officer	75 LORIMER ROAD, BELMONT MA 02141
Atlas Venture Associates Opportunity Ii, Lp	10 percent owner	300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Fund Xi, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Jason P Rhodes	director, 10 percent owner	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Opportunity Fund Ii, L.p.	10 percent owner	300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity Ii, Llc	10 percent owner	300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Carlo Incerti	director	FORBION CAPITAL FUND IV COOPERAITEF U.A., GOOMIER 2-35, NAARDEN P7 1411DC
Romesh Subramanian	10 percent owner, officer: Chief Scientific Officer	C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Cureduchenne Ventures, Llc	10 percent owner	1400 QUAIL STREET, SUITE 110, NEWPORT BEACH CA 92660